Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 874054, 10 pages
http://dx.doi.org/10.1155/2015/874054
Research Article

Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study

1Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
3Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
4Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan
5Chang Gung University College of Medicine, Linkou, Taiwan
6Department of Public Health, Chang Gung University, Taoyuan 333, Taiwan
7Pathology Core of the Chang Gung Molecular Medicine Research Center, Taoyuan 333, Taiwan

Received 2 March 2015; Accepted 22 June 2015

Academic Editor: Bryan C. Fuchs

Copyright © 2015 Sum-Fu Chiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, http://www.cancer.org/.
  2. Health Promotion Administration and Ministry of Health and Welfare Taiwan, http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201404160001.
  3. Ministry of Health and Welfare, Taiwan, R.O.C., http://www.mohw.gov.tw/cht/Ministry/DM2_P.aspx?f_list_no=7&fod_list_no=4473&doc_no=38087.
  4. S. H. Taplin, W. Barlow, N. Urban et al., “Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care,” Journal of the National Cancer Institute, vol. 87, no. 6, pp. 417–426, 1995. View at Publisher · View at Google Scholar
  5. K. Lang, L. M. Lines, D. W. Lee, J. R. Korn, C. C. Earle, and J. Menzin, “Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data,” Clinical Gastroenterology and Hepatology, vol. 7, no. 2, pp. 198–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Ramsey, M. R. Andersen, R. Etzioni et al., “Quality of life in survivors of colorectal carcinoma,” Cancer, vol. 88, no. 6, pp. 1294–1303, 2000. View at Google Scholar · View at Scopus
  7. M. J. O'Connell, M. E. Campbell, R. M. Goldberg et al., “Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2336–2341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. “Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trial (IMPACT B2) Investigators,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1356–1363, 1999.
  9. P. Martens and R. Bisschops, “Bowel preparation for colonoscopy: efficacy, tolerability and safety,” Acta Gastro-Enterologica Belgica, vol. 77, no. 2, pp. 249–255, 2014. View at Google Scholar · View at Scopus
  10. E. J. Ainley, P. J. Winwood, and J. P. Begley, “Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation,” Digestive Diseases and Sciences, vol. 50, no. 7, pp. 1319–1323, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. S. Markowitz, S. H. Nasr, P. Klein et al., “Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing,” Human Pathology, vol. 35, no. 6, pp. 675–684, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Duffy, A. van Dalen, C. Haglund et al., “Clinical utility of biochemical markers in colorectal cancer: european Group on Tumour Markers (EGTM) guidelines,” European Journal of Cancer, vol. 39, no. 6, pp. 718–727, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. S. Macdonald, “Carcinoembryonic antigen screening: pros and cons,” Seminars in Oncology, vol. 26, no. 5, pp. 556–560, 1999. View at Google Scholar · View at Scopus
  14. M. P. Pavlou, E. P. Diamandis, and I. M. Blasutig, “The long journey of cancer biomarkers from the bench to the clinic,” Clinical Chemistry, vol. 59, no. 1, pp. 147–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. N. L. Anderson, “The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum,” Clinical Chemistry, vol. 56, no. 2, pp. 177–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Abu-Asab, M. Chaouchi, S. Alesci et al., “Biomarkers in the age of omics: time for a systems biology approach,” OMICS, vol. 15, no. 3, pp. 105–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. P. Pavlou and E. P. Diamandis, “The cancer cell secretome: a good source for discovering biomarkers?” Journal of Proteomics, vol. 73, no. 10, pp. 1896–1906, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Zhang and D. W. Chan, “Cancer proteomics: in pursuit of “true” biomarker discovery,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 10, pp. 2283–2286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. E. P. Diamandis, “Cancer biomarkers: can we turn recent failures into success?” Journal of the National Cancer Institute, vol. 102, no. 19, pp. 1462–1467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. de Wit, R. J. A. Fijneman, H. M. W. Verheul, G. A. Meijer, and C. R. Jimenez, “Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications,” Clinical Biochemistry, vol. 46, no. 6, pp. 466–479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-C. Wu, C.-W. Hsu, C.-D. Chen et al., “Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas,” Molecular & Cellular Proteomics, vol. 9, no. 6, pp. 1100–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Xue, B. Lü, J. Zhang et al., “Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach,” Journal of Proteome Research, vol. 9, no. 1, pp. 545–555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Human Protein Atlas, HPA, http://www.proteinatlas.org/.
  24. Human Plasma Proteome Project, HPPP, http://www.thehpp.org/.
  25. S. F. Chiang, M. H. Tsai, R. Tang et al., “Membrane proteins as potential colon cancer biomarkers: verification of 4 candidates from a secretome dataset,” Surgical Science, vol. 5, no. 10, pp. 418–438, 2014. View at Publisher · View at Google Scholar
  26. T. Ohtomo, Y. Sugamata, Y. Ozaki et al., “Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells,” Biochemical and Biophysical Research Communications, vol. 258, no. 3, pp. 583–591, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Cai, J. Cao, Z. Li et al., “Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis,” BMC Cancer, vol. 9, article 102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Kawai, Y. Azuma, E. Fujii et al., “Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models,” Cancer Science, vol. 99, no. 12, pp. 2461–2466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Wang, Y. Nishioka, S. Ozaki et al., “HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody,” Cancer Immunology, Immunotherapy, vol. 58, no. 6, pp. 967–976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Sala-Valdés, N. Ailane, C. Greco, E. Rubinstein, and C. Boucheix, “Targeting tetraspanins in cancer,” Expert Opinion on Therapeutic Targets, vol. 16, no. 10, pp. 985–997, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. R. L. Bailey, J. M. Herbert, K. Khan, V. L. Heath, R. Bicknell, and M. G. Tomlinson, “The emerging role of tetraspanin microdomains on endothelial cells,” Biochemical Society Transactions, vol. 39, no. 6, pp. 1667–1673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. J. Thompson, G. C. Schatteman, A. M. Gown, and M. Bothwell, “A monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue,” American Journal of Clinical Pathology, vol. 92, no. 4, pp. 415–423, 1989. View at Google Scholar · View at Scopus
  33. D. L. Baker, W. M. Molenaar, J. Q. Trojanowski et al., “Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland,” The American Journal of Pathology, vol. 139, no. 1, pp. 115–122, 1991. View at Google Scholar · View at Scopus
  34. V. Balik, P. Mirossay, P. Bohus, I. Sulla, L. Mirossay, and M. Sarissky, “Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy,” Cellular and Molecular Neurobiology, vol. 29, no. 6-7, pp. 845–858, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. G. Billcliff, R. Rollason, I. Prior, D. M. Owen, K. Gaus, and G. Banting, “CD317/tetherin is an organiser of membrane microdomains,” Journal of Cell Science, vol. 126, no. 7, pp. 1553–1564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. D. T. Evans, R. Serra-Moreno, R. K. Singh, and J. C. Guatelli, “BST-2/tetherin: a new component of the innate immune response to enveloped viruses,” Trends in Microbiology, vol. 18, no. 9, pp. 388–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Jia, R. Serra-Moreno, W. Neidermyer Jr. et al., “Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2,” PLoS Pathogens, vol. 5, no. 5, Article ID e1000429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-L. Chen, Y.-F. Lai, P. Tang et al., “Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients,” Journal of Proteome Research, vol. 11, no. 12, pp. 5611–5629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. H. Lüning, M. E. Keemers-Gels, W. B. Barendregt, A. C. I. T. L. Tan, and C. Rosman, “Colonoscopic perforations: a review of 30,366 patients,” Surgical Endoscopy and Other Interventional Techniques, vol. 21, no. 6, pp. 994–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. C. H. Viiala, M. Zimmerman, D. J. E. Cullen, and N. E. Hoffman, “Complication rates of colonoscopy in an Australian teaching hospital environment,” Internal Medicine Journal, vol. 33, no. 8, pp. 355–359, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Yamashita and M. Watanabe, “Clinical significance of tumor markers and an emerging perspective on colorectal cancer,” Cancer Science, vol. 100, no. 2, pp. 195–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. P. W. Dykes and J. King, “Carcinoembryonic antigen (CEA),” Gut, vol. 13, no. 12, pp. 1000–1013, 1972. View at Publisher · View at Google Scholar · View at Scopus
  44. R. H. Fletcher, “Carcinoembryonic antigen,” Annals of Internal Medicine, vol. 104, no. 1, pp. 66–73, 1986. View at Publisher · View at Google Scholar · View at Scopus
  45. A. G. Paulovich, J. R. Whiteaker, A. N. Hoofnagle, and P. Wang, “The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline,” Proteomics - Clinical Applications, vol. 2, no. 10-11, pp. 1386–1402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. A. K. Füzéry, J. Levin, M. M. Chan, and D. W. Chan, “Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges,” Clinical Proteomics, vol. 10, no. 1, article 13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Ishikawa, T. Kaisho, H. Tomizawa et al., “Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth,” Genomics, vol. 26, no. 3, pp. 527–534, 1995. View at Publisher · View at Google Scholar · View at Scopus
  48. S. J. D. Neil, T. Zang, and P. D. Bieniasz, “Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu,” Nature, vol. 451, no. 7177, pp. 425–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Hammonds, J.-J. Wang, H. Yi, and P. Spearman, “Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane,” PLoS Pathogens, vol. 6, no. 2, Article ID e1000749, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Yokoyama, T. Enomoto, S. Serada et al., “Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer,” International Journal of Cancer, vol. 132, no. 2, pp. 472–484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. K.-H. Fang, H.-K. Kao, L.-M. Chi et al., “Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer,” The Laryngoscope, vol. 124, no. 9, pp. E354–E360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Ensembl, http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000130303;r=19:17402939-17405648.
  53. J. Hammonds, L. Ding, H. Chu et al., “The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release,” Journal of Virology, vol. 86, no. 4, pp. 2259–2272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. S. I. Buschow, B. W. M. Van Balkom, M. Aalberts, A. J. R. Heck, M. Wauben, and W. Stoorvogel, “MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis,” Immunology & Cell Biology, vol. 88, no. 8, pp. 851–856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Liang, P. Peng, S. Chen et al., “Characterization and proteomic analysis of ovarian cancer-derived exosomes,” Journal of Proteomics, vol. 80, pp. 171–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Skogberg, J. Gudmundsdottir, S. van der Post et al., “Characterization of human thymic exosomes,” PLoS ONE, vol. 8, no. 7, Article ID e67554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Pisitkun, R.-F. Shen, and M. A. Knepper, “Identification and proteomic profiling of exosomes in human urine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13368–13373, 2004. View at Publisher · View at Google Scholar · View at Scopus